News - Onyx Pharmaceuticals, Research

Filter

Popular Filters

Liver cancer market to nearly treble in size to $1.4 billion by 2019

Liver cancer market to nearly treble in size to $1.4 billion by 2019

13-11-2013

The value of the hepatocellular cancer (HCC) market is set to grow by a massive 172% and hit $1.4 billion…

BayerEuropeMarkets & MarketingNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Onyx enter strategic alliance focused on advancing drug discovery and development

05-06-2013

US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) and the University of California, San Francisco (UCSF)…

BiotechnologyOncologyOnyx PharmaceuticalsResearch

Highlights from ASCO: Bayer's Nexavar; Novartis' Afinitor; and Amgen's talimogene laherparepvec

02-06-2013

The prestigious annual meeting of the American Society of Clinical Oncology (ASCO) kicked off this weekend…

AfinitorAmgenBayerBiotechnologyNexavarNovartisOncologyOnyx PharmaceuticalsPharmaceuticalResearchtalimogene laherparepvec

AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar

14-02-2013

US biotech AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TYO: 4503) have announced…

Astellas PharmaAVEO OncologyBayerBiotechnologyNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchtivozanib

Positive Ph III results for Bayer's Nexavar in thyroid cancer

03-01-2013

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) this morning revealed…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

News briefs: Bayer's Stivarga and AstraZeneca's Faslodex

30-10-2012

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

Adding Tarceva to Nexavar no better than Nexavar alone for liver cancer

23-07-2012

A Phase III trial evaluating the efficacy and safety of the addition of Roche's Tarceva (erlotinib) tablets…

Astellas PharmaBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchTarceva

News briefs: US priority review for regorafenib; Ph IIb blisibimod data

29-06-2012

Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

Onyx Pharma links with Texas MD Anderson Cancer Center on research

05-06-2012

US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center…

BiotechnologycarfilzomibOncologyOnyx PharmaceuticalsoprozomibResearch

Bayer and Onyx' Nexavar fails in Ph III lung cancer study

23-05-2012

There was disappointment for German drug major Bayer (BAYB: DE) and partner Onyx Pharmaceuticals (Nasdaq:…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Bayer’s Xarelto OKed in Japan; promising regorafenib data

19-01-2012

Bayer Healthcare, a unit of Germany’s Bayer AG (BAY: DE), had a couple of good news item to report…

BayerCardio-vascularOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationResearchXarelto

Onyx joins with MMRF to advance MM targeted therapies

15-12-2011

US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) has joined forces with the Multiple Myeloma Research…

BiotechnologyNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Bayer halts regorafenib trial for colorectal cancer on good Ph III results

27-10-2011

USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Back to top